SCYNEXIS, Inc is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several serious fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone201-884-5485
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$260,000.00
Profitability
Miscellaneous
Employees24
Next Earnings Date11/12/2019 (Estimated)
OptionableOptionable
SCYNEXIS (NASDAQ:SCYX) Frequently Asked Questions
What is SCYNEXIS's stock symbol?
SCYNEXIS trades on the NASDAQ under the ticker symbol "SCYX."
How were SCYNEXIS's earnings last quarter?
SCYNEXIS Inc (NASDAQ:SCYX) announced its quarterly earnings data on Wednesday, August, 7th. The company reported ($0.16) EPS for the quarter, topping the Zacks' consensus estimate of ($0.18) by $0.02. The firm had revenue of $0.06 million for the quarter, compared to the consensus estimate of $0.06 million. SCYNEXIS had a negative return on equity of 141.28% and a negative net margin of 11,653.81%. View SCYNEXIS's Earnings History.
When is SCYNEXIS's next earnings date?
What price target have analysts set for SCYX?
6 Wall Street analysts have issued 1 year price targets for SCYNEXIS's stock. Their predictions range from $4.00 to $6.00. On average, they anticipate SCYNEXIS's share price to reach $5.00 in the next twelve months. This suggests a possible upside of 354.5% from the stock's current price. View Analyst Price Targets for SCYNEXIS.
What is the consensus analysts' recommendation for SCYNEXIS?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SCYNEXIS in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for SCYNEXIS.
What are Wall Street analysts saying about SCYNEXIS stock?
Here are some recent quotes from research analysts about SCYNEXIS stock:
- 1. According to Zacks Investment Research, "SCYNEXIS, Inc. is a pharmaceutical company. It is engaged in the discovery, development, and commercialization of anti-infectives to address unmet therapeutic needs. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of serious and life-threatening invasive fungal infections in humans. It also provides contract research and development services. SCYNEXIS, Inc. is headquartered in Durham, North Carolina. " (5/22/2019)
- 2. Needham & Company LLC analysts commented, "Scynexis reported 1Q19 financial results this wk and we spoke w/ mgmt for an update. Enrollment in ibrexafungerp Phase 3 VANISH program in Acute Vulvovaginal Candidiasis (VVC) is progressing and mgmt reiterated guidance for top-line results in 1H20. Phase 3 CANDLE trial in Recurrent VVC is expected to start in 2Q19 (unch). Reiterate BUY. We believe commercial opportunity in VVC is substantially underappreciated by investors given there are no oral options for pts w/ poor response to standard of care oral fluconazole. Recent encouraging data from FURI and CARES trials demonstrating impressive activity against challenging infections (including tied to C. auris) enhances overall profile." (5/12/2019)
- 3. Maxim Group analysts commented, "Scynexis reported FY18 with operating expenses of $30.2M and a net loss of ($12.5M). The company ended the period with $44.2M in cash, excluding the sale of a portion of its business, and tax net operating losses (NOLs) in $6.7M, netting a pro forma cash balance of $51M in January. Scynexis also completed the sale of a $16.0M convertible note to March, which the company used to retire in full a previous term loan, strengthening its balance sheet further. Combined, Scynexis has runway at the current burn rate through key catalysts, including the NDA submission of ibrexafungerp for acute vulvovaginal candidiasis (VVC) in 2H20." (3/18/2019)
Has SCYNEXIS been receiving favorable news coverage?
News articles about SCYX stock have trended positive on Monday, according to InfoTrie Sentiment. InfoTrie scores the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. SCYNEXIS earned a daily sentiment score of 2.5 on InfoTrie's scale. They also gave headlines about the company a news buzz of 6.0 out of 10, meaning that recent press coverage is somewhat likely to have an impact on the company's share price in the next several days. View News Stories for SCYNEXIS.
Who are some of SCYNEXIS's key competitors?
Some companies that are related to SCYNEXIS include Cyclerion Therapeutics (CYCN), Flex Pharma (FLKS), NuCana (NCNA), Aratana Therapeutics (PETX), TapImmune (MRKR), Evofem Biosciences (EVFM), Concert Pharmaceuticals (CNCE), Urovant Sciences (UROV), Verrica Pharmaceuticals (VRCA), Aeglea Bio Therapeutics (AGLE), Chiasma (CHMA), Xenon Pharmaceuticals (XENE), PhaseBio Pharmaceuticals (PHAS), Ardelyx (ARDX) and Kamada (KMDA).
What other stocks do shareholders of SCYNEXIS own?
Who are SCYNEXIS's key executives?
SCYNEXIS's management team includes the folowing people:
- Marco Taglietti, President, Chief Executive Officer & Director
- Eric Francois, Chief Financial Officer
- David Angulo Gonzalez, Chief Medical Officer
- Rajeshwar Motheram, Vice President-Pharmaceutical Development
- Scott Sukenick, General Counsel
Who are SCYNEXIS's major shareholders?
SCYNEXIS's stock is owned by a number of of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (4.26%), BlackRock Inc. (1.53%), Renaissance Technologies LLC (0.85%) and Creative Planning (0.26%). Company insiders that own SCYNEXIS stock include David C Hastings, Eric Francois, Gonzalez David Angulo, Marco Taglietti and Scott Sukenick. View Institutional Ownership Trends for SCYNEXIS.
Which major investors are buying SCYNEXIS stock?
SCYX stock was purchased by a variety of institutional investors in the last quarter, including Vanguard Group Inc., BlackRock Inc., Renaissance Technologies LLC and Creative Planning. Company insiders that have bought SCYNEXIS stock in the last two years include David C Hastings, Eric Francois, Gonzalez David Angulo, Marco Taglietti and Scott Sukenick. View Insider Buying and Selling for SCYNEXIS.
How do I buy shares of SCYNEXIS?
Shares of SCYX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is SCYNEXIS's stock price today?
One share of SCYX stock can currently be purchased for approximately $1.10.
How big of a company is SCYNEXIS?
SCYNEXIS has a market capitalization of $61.28 million and generates $260,000.00 in revenue each year. The company earns $-12,470,000.00 in net income (profit) each year or ($0.49) on an earnings per share basis. SCYNEXIS employs 24 workers across the globe.View Additional Information About SCYNEXIS.
What is SCYNEXIS's official website?
How can I contact SCYNEXIS?
SCYNEXIS's mailing address is 1 EVERTRUST PLAZA 13TH FLOOR, JERSEY CITY NJ, 07302. The company can be reached via phone at 201-884-5485 or via email at [email protected]
MarketBeat Community Rating for SCYNEXIS (NASDAQ SCYX)
MarketBeat's community ratings are surveys of what our community members think about SCYNEXIS and other stocks. Vote "Outperform" if you believe SCYX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SCYX will underperform the S&P 500 over the long term. You may vote once every thirty days.
